TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$69 Million

Adverum Biotechnologies

Follow-on Offering

Lead Left Bookrunner, February 2018

Adverum Biotechnologies
Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.